Xoft focuses on point-of-care access with electronic radiation therapy
Xoft showcased early clinical trial results, as well as its growing suite of oncology treatment technologies, during at the 50th American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting.
The developer of the Axxent Electronic Brachytherapy (eBx) System presented initial data in conjunction with the show from the company’s phase IV study during the Industry Satellite Symposium, as well as debuted its Axxent Xpress mobile electronic brachytherapy vehicles.
According to Vivek Mehta, MD, director, Center for Advanced Targeted Radiotherapies at Swedish Cancer Center in Seattle and radiation oncology principal investigator for the study, the clinical experience with the Axxent System demonstrates that the x-ray-based, non-isotopic treatment is a viable option for adjuvant therapy for early-stage breast cancer. eBx delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.
According to the early trial results, after a lumpectomy surgery, the system was used to deliver radiation therapy directly to the tumor bed over five days instead of the standard five to seven week course of treatment. Mehta said that while they will be conducting a five-year patient follow up, the results confirm that electronic brachytherapy is a “safe and clinically promising alternative for accelerated partial breast irradiation.”
Mike Klein, president and CEO, told Health Imaging News that the 10 site study shows that the system can be widely used without the need for a shielded room, when used in conjunction with a trained surgeon, and trained radiation oncologist “pushing the button.”
He noted that radiation therapy in breast cancer, approximately 50 percent of women actually comply with prescribed treatment. If accelerated partial breast irradiation has progressed from six to eight week therapy down to one week, Xoft is asking why more women are not complying.
“The key is access,” Klein noted. “Access for both the patient and treatment delivery sites, at the point of care.”
To expand and improve access to critical radiation therapy, Xoft collaborated with Medical Coaches, a manufacturer of custom mobile medical and specialty vehicles, to design and manufacture the Axxent Xpress Mobile Electronic Brachytherapy Vehicles, which can be configured with up to three Axxent HDR controllers.
The controllers will ride on an easy to drive sprinter van modified to provide a safe transport environment with shock absorbers and rear heating and cooling to ensure equipment is ready to operate at delivery.
There are two deployment model options: a single unit deployed across multiple facilities on a rotating weekly basis or a single van with three units deployed across multiple facilities on an as-needed basis. Essentially, the eBx can be dropped off by a service provider, when a site needs it, at a fraction of the cost to purchase it outright, Klein said.
“Adding the ability to provide mobile radiation therapy services is a natural progression; one we hope will further improve access for the tens of thousands of breast cancer patients who do not comply with their prescribed radiation treatment or otherwise would not receive it,” Klein added.
The developer of the Axxent Electronic Brachytherapy (eBx) System presented initial data in conjunction with the show from the company’s phase IV study during the Industry Satellite Symposium, as well as debuted its Axxent Xpress mobile electronic brachytherapy vehicles.
According to Vivek Mehta, MD, director, Center for Advanced Targeted Radiotherapies at Swedish Cancer Center in Seattle and radiation oncology principal investigator for the study, the clinical experience with the Axxent System demonstrates that the x-ray-based, non-isotopic treatment is a viable option for adjuvant therapy for early-stage breast cancer. eBx delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.
According to the early trial results, after a lumpectomy surgery, the system was used to deliver radiation therapy directly to the tumor bed over five days instead of the standard five to seven week course of treatment. Mehta said that while they will be conducting a five-year patient follow up, the results confirm that electronic brachytherapy is a “safe and clinically promising alternative for accelerated partial breast irradiation.”
Mike Klein, president and CEO, told Health Imaging News that the 10 site study shows that the system can be widely used without the need for a shielded room, when used in conjunction with a trained surgeon, and trained radiation oncologist “pushing the button.”
He noted that radiation therapy in breast cancer, approximately 50 percent of women actually comply with prescribed treatment. If accelerated partial breast irradiation has progressed from six to eight week therapy down to one week, Xoft is asking why more women are not complying.
“The key is access,” Klein noted. “Access for both the patient and treatment delivery sites, at the point of care.”
To expand and improve access to critical radiation therapy, Xoft collaborated with Medical Coaches, a manufacturer of custom mobile medical and specialty vehicles, to design and manufacture the Axxent Xpress Mobile Electronic Brachytherapy Vehicles, which can be configured with up to three Axxent HDR controllers.
The controllers will ride on an easy to drive sprinter van modified to provide a safe transport environment with shock absorbers and rear heating and cooling to ensure equipment is ready to operate at delivery.
There are two deployment model options: a single unit deployed across multiple facilities on a rotating weekly basis or a single van with three units deployed across multiple facilities on an as-needed basis. Essentially, the eBx can be dropped off by a service provider, when a site needs it, at a fraction of the cost to purchase it outright, Klein said.
“Adding the ability to provide mobile radiation therapy services is a natural progression; one we hope will further improve access for the tens of thousands of breast cancer patients who do not comply with their prescribed radiation treatment or otherwise would not receive it,” Klein added.